Fenwick Represents SomaLogic in Merger Agreement with Standard BioTools

Fenwick is representing SomaLogic (NASDAQ: SLGC), a leader in proteomics technology, in its definitive merger agreement with Standard BioTools Inc. (NASDAQ: LAB), a manufacturer of standardized next-generation technologies.

The combined company will be a leading provider of differentiated multi-omics tools for research. Upon completion of the merger, the combined company is expected to operate under the Standard BioTools name. The transaction is expected to close in the first quarter of 2024, subject to approval by both companies’ stockholders, expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions. More information can be obtained from the news announcement.

The Fenwick transaction team included corporate partners Ethan Skerry, David Michaels and Julia Forbess and associates Matthew McCabe, Robert O’Conner, Brendan Montgomery, Jordan Beals, Tyler Gratton, Luke Finn, Brandon Ho and law clerk Ty Chung; technology transactions partner Stefano Quintini and associates Jennifer Yoon, Russell Wong, Trevor Snider, Kehl Sink, Julia Chung, Catherine Kim, Ju Yun (Julie) Son, Barbara Wong, Aaron Dunn, Alberto Tohme and Mina Matsumoto; executive compensation and employee benefits partner Matt Cantor, counsel Laura McIntyre and associates Elizabeth Fu and Sedina Alicic-Huang; patent partner Antonia Sequeira and associates Fredrick Tsang and Elly Chow Schultz; employment litigation partner Dan McCoy and associate Reanne Swafford-Harris; antitrust and competition partner Tom Ensign and associates Elizabeth Suarez, Kaylynn Moss and Susan Lee; healthcare regulatory partner Jennifer Yoo and associate Stephanie Maynes Aldous; tax partner William Skinner and associate Einav Axler; trademark partner Mark Jansen and associate Jessica Chung; and privacy and cybersecurity counsel Ana Razmazma.